3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Glioblastoma
6
Rectal Neoplasms
5
Oropharyngeal Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Lung Neoplasms
4
Burkitt Lymphoma
4
Astrocytoma
4
Urinary Bladder Neoplasms
3
Mouth Neoplasms
3
Glioma
3
Carcinoma, Squamous Cell
3
Adenocarcinoma of Lung
3
Rhabdomyosarcoma
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, Follicular
2
Laryngeal Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Carcinoma
2
Breast Carcinoma In Situ
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Interventions
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
tislelizumab
1
tisagenlecleucel
1
obinutuzumab
1
Radiotherapy
1
Monatide (IMS 3015)
1
HMPL-013
1
Cetuximab
1
Blood Specimen Collection
1
Biological Assay
1
AP 1903 reagent
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Radiotherapy
×
30 days
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled